New therapeutic agents for cryptosporidiosis are a critical medical need. The marine organic compound, tartrolon E (trtE), is highly effective against multiple apicomplexan parasites, including Cryptosporidium. Understanding the mechanism of action of trtE is required to advance in the drug development pipeline. Here, we validate using Nluc C. parvum parasites for the study of trtE and pinpoint the life stage targeted by trtE. Results show that trtE kills Nluc and wild type C. parvum with equal efficiency, confirming the use of the Nluc C. parvum to study this compound. Results revealed that trtE kills the parasite within an hour of treatment and while the compound has no effect on viability of sporozoites, trtE does inhibit establishment of infection. Targeting treatment at particular life cycle stages demonstrated that trtE is effective against asexual of the parasite but has reduced efficacy against mature sexual stages. Gene expression analysis shows that trtE inhibits the early sexual stage of the parasite. Results from these studies will aid the development of trtE as a therapeutic for cryptosporidiosis.
Cryptosporidium is a waterborne gastrointestinal parasite that causes diarrheal disease worldwide. Currently, there are no effective therapeutics to treat cryptosporidiosis. Since natural products are a known source of anti-parasitic compounds, we screened a library of extracts and pure compounds isolated from bacteria and fungi collected from subterranean environments for anti-Cryptosporidium activity. Seven norditerpene lactones isolated from the fungus Oidiodendron truncatum collected from the Soudan Iron mine in Minnesota showed potent activity and were further tested to identify the most active compounds. The availability of a diverse suite of natural structural analogs with varying activities allowed us to determine some structure–activity relationships for both anti-parasitic activity and cytotoxicity. The two most potent compounds, oidiolactones A and B, had EC50s against C. parvum of 530 and 240 nM, respectively, without cytotoxicity to host cells. Both compounds also inhibited the related parasite Toxoplasma gondii. Oidiolactone A was active against asexual, but not sexual, stages of C. parvum, and killed parasites within 8 h of treatment. This compound reduced C. parvum infection by 70% in IFNγ−/− mice, with no signs of toxicity. The high potency, low cytotoxicity, and in vivo activity combined with high production and synthetic accessibility make these oidiolactones attractive scaffolds for the development of new anti-Cryptosporidium therapeutics.